APA citiranje

Ramakrishnan, V., Kimlinger, T., Haug, J., Timm, M., Wellik, L., Halling, T., . . . Kumar, S. (2010). TG101209, a novel JAK2 inhibitor, has significant in-vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

Citação norma Chicago

Ramakrishnan, Vijay, et al. TG101209, a Novel JAK2 Inhibitor, Has Significant In-vitro Activity in Multiple Myeloma and Displays Preferential Cytotoxicity for CD45+ Myeloma Cells. 2010.

MLA citiranje

Ramakrishnan, Vijay, et al. TG101209, a Novel JAK2 Inhibitor, Has Significant In-vitro Activity in Multiple Myeloma and Displays Preferential Cytotoxicity for CD45+ Myeloma Cells. 2010.